4dym
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00135== | ==Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00135== | ||
- | <StructureSection load='4dym' size='340' side='right' caption='[[4dym]], [[Resolution|resolution]] 2.42Å' scene=''> | + | <StructureSection load='4dym' size='340' side='right'caption='[[4dym]], [[Resolution|resolution]] 2.42Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[4dym]] is a 1 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[4dym]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4DYM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4DYM FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=IYZ:1-(3-{6-[(CYCLOPROPYLMETHYL)AMINO]IMIDAZO[1,2-B]PYRIDAZIN-3-YL}PHENYL)ETHANONE'>IYZ</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=IYZ:1-(3-{6-[(CYCLOPROPYLMETHYL)AMINO]IMIDAZO[1,2-B]PYRIDAZIN-3-YL}PHENYL)ETHANONE'>IYZ</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
- | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4dym FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4dym OCA], [https://pdbe.org/4dym PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4dym RCSB], [https://www.ebi.ac.uk/pdbsum/4dym PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4dym ProSAT]</span></td></tr> | |
- | + | ||
- | + | ||
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
== Disease == | == Disease == | ||
- | [[ | + | [[https://www.uniprot.org/uniprot/ACVR1_HUMAN ACVR1_HUMAN]] Fibrodysplasia ossificans progressiva. Defects in ACVR1 are a cause of fibrodysplasia ossificans progressiva (FOP) [MIM:[https://omim.org/entry/135100 135100]]. FOP is a rare autosomal dominant disorder of skeletal malformations and progressive extraskeletal ossification. Heterotopic ossification in FOP begins in childhood and can be induced by trauma or may occur without warning. Bone formation is episodic and progressive, leading to extra-articular ankylosis of all major joints of the axial and appendicular skeleton, rendering movement impossible.<ref>PMID:16642017</ref> <ref>PMID:19085907</ref> <ref>PMID:19330033</ref> |
== Function == | == Function == | ||
- | [[ | + | [[https://www.uniprot.org/uniprot/ACVR1_HUMAN ACVR1_HUMAN]] On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin. May be involved for left-right pattern formation during embryogenesis (By similarity). |
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Homo sapiens]] |
- | [[Category: | + | [[Category: Large Structures]] |
- | [[Category: Alfano | + | [[Category: Alfano I]] |
- | [[Category: Arrowsmith | + | [[Category: Arrowsmith CH]] |
- | [[Category: Bountra | + | [[Category: Bountra C]] |
- | [[Category: Bullock | + | [[Category: Bullock A]] |
- | [[Category: Canning | + | [[Category: Canning P]] |
- | [[Category: Chaikuad | + | [[Category: Chaikuad A]] |
- | [[Category: Cooper | + | [[Category: Cooper C]] |
- | [[Category: Daga | + | [[Category: Daga N]] |
- | + | [[Category: Edwards AM]] | |
- | [[Category: Edwards | + | [[Category: Fedorov O]] |
- | [[Category: Fedorov | + | [[Category: Filippakopoulos P]] |
- | [[Category: Filippakopoulos | + | [[Category: Gileadi O]] |
- | [[Category: Gileadi | + | [[Category: Krojer T]] |
- | [[Category: Krojer | + | [[Category: Mahajan P]] |
- | [[Category: Mahajan | + | [[Category: Muniz JRC]] |
- | [[Category: Muniz | + | [[Category: Petrie K]] |
- | [[Category: Petrie | + | [[Category: Sanvitale C]] |
- | + | [[Category: Weigelt J]] | |
- | [[Category: Sanvitale | + | [[Category: Von Delft F]] |
- | [[Category: Weigelt | + | |
- | [[Category: | + | |
- | + | ||
- | + |
Revision as of 08:44, 21 September 2022
Crystal structure of the ACVR1 kinase domain in complex with the imidazo[1,2-b]pyridazine inhibitor K00135
|
Categories: Homo sapiens | Large Structures | Alfano I | Arrowsmith CH | Bountra C | Bullock A | Canning P | Chaikuad A | Cooper C | Daga N | Edwards AM | Fedorov O | Filippakopoulos P | Gileadi O | Krojer T | Mahajan P | Muniz JRC | Petrie K | Sanvitale C | Weigelt J | Von Delft F